Every year millions of American citizens leave their LDL annual check ups with a question in their heads: “is my “bad” cholesterol low enough”? A new study published in the journal JAMA by Chicago’s Northwestern Medicine suggests that the apolipoprotein B (apoB) could be doing a better job of guiding stronger cholesterol-lowering treatment, which could prevent more heart attacks and strokes at an ever lower cost.
The strength of the new evidence does correlate to LDL tests being useless. Since the research was a lifetime computer simulation and not a clinical trial the 2026 ACC/AHA guideline still keeps LDL-C and non-HDL-C as the main recommended treatments since the apoB efficiency is still unknown in human tests.
Why apoB sees something LDL can miss
The standard LDL-C that is used in the industry tells the physicians how much cholesterol is being carried inside the LDL particles. ApoB on the other hand serves as a count of harmful particles that carry cholesterol in the blood, in turn giving clinicians a better view of the traffic of particles that are going through the patient arteries.
It is as if the LDL-C measured the cargo while apoB counted the trucks. Even if two people carried a similar amount of cholesterol the results can be different. For unknown reasons one person has more opportunities of having those cholesterol particles trapped to their artery walls contributing to the plaque.
The computer model results are in
Through a computer program researchers created a simulated cohort of 250,000 U.S. adults who were eligible for statins but that didn’t have atherosclerotic cardiovascular disease. They compared treatment strategies using an LDL-C goal below 100 mg/dL, a non-HDL-C goal below 118 mg/dL, and/or an apoB goal below 78.7 mg/dL. If it happened that a simulated patient “missed the assigned target” then the team tried using a statin first and an ezetimibe later if the statin didn’t work.
3 different strategies were combined over a simulated persons lifetime to try and estimate heart attacks, strokes, possibility of survival, quality of life and healthcare costs. The ApoB guided care produced well rounded results when the scientists took into account quality of life and life span. Breaking it down the researchers saw it added 1,324 years of a more quality adjusted life across the whole study population and that it also reduced a total cost of $40.2 millions all around. Equivalent to about $30,300 per year for each individual!
The result comes with a caveat
The study did not grab any 250,000 people and randomly assigned them to different blood tests. It was built using data of 4,149 people who had already participated in federal health surveys that were conducted between the years 2005 and 2016. Previously published research and other cohorts were then added to the mix by the scientists.
Which in turn means the findings are dependent on assumptions about future treatments, costs and cardiovascular risk. Most of the extra expenses came simply because people survived longer, giving them additional years in which they kept paying their preventive treatments.
New guidelines open the door without replacing LDL
The new dyslipidemia guideline published in 2026 states that after LDL-C and non-HDL-C targets are met the apoB can help scientists assess possible risks before starting other therapies. It also shows people that have triglycerides above 200 mg/dL, people that have diabetes, and people with a very low achieved LDL-C (which is below 70 mg/dL).
At the same time the guideline helped restore a clearer version of LDL-C and non-HDL-C treatment goals. It also determined that statins should be kept as the foundation of cholesterol lowering care. The apoB is not a replacement to a cholesterol treatment. It is instead positioned as an optional way for some patients who can probably still carry risky previous LDL results.
Let’s not get ahead of ourselves
Jumping to conclusions based on this study alone is definitely not the way to go. Stopping a statin, changing a dose or dismissing the LDL result is not a good idea. What the patients need to ask themselves is if their apoB tests can add useful information to their risk assessment especially when they have elevated triglycerides, if they have diabetes, or if they have higher cardiovascular risks than the usual cholesterol numbers imply.
Because the blood test is only but a piece in the whole picture the clinicians also need to consider if the overall cardiovascular risk, health history and treatment tolerance are worth the benefits and burdens of an increase in medication.
A small testing change can have a potentially large payoff
The study lead Ciaran Kohli-Lynch stated the “research shows that apolipoprotein B (apoB) is better at identifying who is at risk.” His team’s work also adds a financial argument to the biological case, suggesting that a more precise marker could financially aid American citizens that pay for healthcare to keep up with the costs.
Is it possible that an extra number on a lab report can show who needs to be more cautious before a possible first heart attack or stroke? There is no final evidence, but this study puts apoB closer to the routine clinical talks, and the cost question also creates another strong argument for it to be ignored.
This study was published in the journal JAMA.
